Extract

Endocrine Discovery

The incidence of lung cancer was not significantly different among women assigned to combined postmenopausal hormone replacement compared with placebo, but more deaths occurred from non-small-cell lung cancer with combined therapy (62 vs. 31 deaths; hazard ratio, 1.87; 95% CI, 1.22–2.88, P = 0.004) after a mean of 5.6 years of treatment and 2.4 years of additional follow-up in a post hoc analysis of lung cancers diagnosed in women who participated in the Women’s Health Initiative (WHI). (Lancet [October 10, 2009] 374(9697):1243)

Use of darbepoetin alfa in patients with diabetes and chronic kidney disease not on dialysis did not reduce risk of death, cardiovascular disease, or end-stage renal failure, and it was associated with a higher rate of fatal and nonfatal stroke (hazard ratio, 1.92; 95% CI, 1.38–2.68; P < 0.001) in a prospective randomized placebo-controlled study of darbepoetin alfa in 4038 patients, over a median follow-up period of 29 months. (N Engl J Med [published online ahead of print October 30, 2009])

You do not currently have access to this article.